Masimo gets a favorable ruling in Apple Watch patent suit In January 2023, Masimo got a favorable ruling from the US International Trade Commission in the patent dispute with Apple, and it was believed that was one of the several critical steps towards final resolution and that the outcome of the dispute could result in a ban on importing certain Apple Watch models into the US, which would benefit Masimo.

Positive study outcome. Three major studies in January 2023 In January, the company announced favorable results of a prospective study in which researchers assessed the performance of non-invasive spot-check hemoglobin (Hb) measurement with Masimo SpHb on emergency department (ED) patients. The same month, Masimo announced the findings of a before-and-after study published in PLoS ONE in which researchers evaluated the impact of implementing remote patient monitoring with Masimo Patient SafetyNet on the efficacy of hospital rapid response teams (RRTs). Also, in January, Masimo announced the findings of a prospective study in which researchers assessed the accuracy of non-invasive, continuous Hb monitoring with Masimo SpHb on patients undergoing elective cesarean section (CS) with antepartum hemorrhage.

Breakthrough combination of Masimo's W1 Watch with advanced Philips solutions In January 2023, Masimo and Philips expanded their partnership to improve telehealth for patients and clinicians around the world with the Masimo W1 watch, and this combined innovation, which draws upon the two global medical technology leaders' extensive expertise in monitoring, connectivity, and automation, will advance the forefront of telemonitoring and telehealth.

    4. Strong historical stock performance

Masimo's stock has a 6-month USD relative strength of 81 which means in USD terms it outperformed 81% of its 47,464 global peers. A price rise combined with a high relative strength is a bullish signal. Over the last six years, Masimo has been up a total of 73.7% at an annualized rate of 11.7% compared to the S&P 500 Index being up 71.0% at an annualized rate of 11.3%. Masimo has outperformed the S&P 500 Index in 3 of the past 6 years: 2020, 2019, and 2018.

I believe that health care sector is going to increase its value in the future. Unlike Livongo and Guardant, Masimo's been profitable for a long time. Altogether, product sales in the first half of 2019 rose 13%, and continued growth seems likely in any economic environment. That's because Masimo gives out its monitoring equipment for free in exchange for a long-term sensor-purchase agreement. Sensors and other single-use products that accompany Masimo products aren't cheap, but providers pass on those costs to their patients' insurers.